BNP Blood Tests Predict Heart Damage From Cancer Chemotherapy

Persistent BNP elevation after anthracycline chemotherapy predicted the development of cardiotoxicity, making serial BNP monitoring a sensitive early warning system for chemotherapy-induced heart damage.

Okumura, H et al.·Acta haematologica·2000·Moderate Evidencecohort
RPEP-00610CohortModerate Evidence2000RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Persistent BNP elevation after anthracycline chemotherapy predicted development of cardiotoxicity, distinguishing at-risk patients from those with only transient, benign BNP rises.

Key Numbers

How They Did This

Prospective cohort study measuring serial plasma BNP before, during, and after anthracycline chemotherapy. BNP trajectories correlated with echocardiographic cardiac function and clinical cardiotoxicity endpoints.

Why This Research Matters

Anthracyclines are among the most effective cancer drugs, but heart damage limits their use. A blood test that predicts who will develop heart damage enables personalized dosing — maximizing cancer treatment while protecting the heart.

The Bigger Picture

Cardio-oncology is one of medicine's most challenging balancing acts. BNP monitoring offers a practical, inexpensive way to navigate between effective cancer treatment and heart protection.

What This Study Doesn't Tell Us

Specific patient numbers and BNP cutoff values not detailed in abstract. Results may vary with different anthracycline regimens. Other biomarkers (troponin) also have predictive value.

Questions This Raises

  • ?Should BNP monitoring be mandatory during anthracycline chemotherapy?
  • ?Can early intervention based on persistent BNP prevent irreversible cardiotoxicity?
  • ?Does combining BNP with troponin improve prediction?

Trust & Context

Key Stat:
Persistent vs transient Persistent BNP elevation after chemo predicted cardiotoxicity, while transient rises were benign — the pattern matters, not just the level
Evidence Grade:
Moderate evidence from a prospective cohort with serial biomarker monitoring and clinical outcome correlation.
Study Age:
Published in 2000. BNP/NT-proBNP monitoring during cardiotoxic chemotherapy is now recommended in multiple cardio-oncology guidelines.
Original Title:
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
Published In:
Acta haematologica, 104(4), 158-63 (2000)
Database ID:
RPEP-00610

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How common is heart damage from chemotherapy?

Anthracycline cardiotoxicity affects up to 10-20% of patients, depending on cumulative dose. It can cause permanent heart failure years after treatment, making early detection through BNP monitoring critically important.

What should patients know?

If your BNP stays elevated after chemotherapy (not just a brief spike), it may signal developing heart damage. Regular BNP monitoring can catch this early, allowing your doctor to modify treatment before permanent damage occurs.

Read More on RethinkPeptides

Cite This Study

RPEP-00610·https://rethinkpeptides.com/research/RPEP-00610

APA

Okumura, H; Iuchi, K; Yoshida, T; Nakamura, S; Takeshima, M; Takamatsu, H; Ikeno, A; Usuda, K; Ishikawa, T; Ohtake, S; Matsuda, T. (2000). Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.. Acta haematologica, 104(4), 158-63.

MLA

Okumura, H, et al. "Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.." Acta haematologica, 2000.

RethinkPeptides

RethinkPeptides Research Database. "Brain natriuretic peptide is a predictor of anthracycline-in..." RPEP-00610. Retrieved from https://rethinkpeptides.com/research/okumura-2000-brain-natriuretic-peptide-is

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.